This report provides a comprehensive analysis of the global ophthalmic perfluoropropane gas (C3F8) market, projecting steady growth through 2032. It examines the industry's landscape, covering essential applications in vitreo-retinal detachment surgery and market segmentation by type, specification, and end-user. Key drivers such as aging populations and rising myopia prevalence are analyzed alongside significant barriers, including high technical requirements and strict environmental regulations. Furthermore, the study evaluates competitive strategies, regional trends, and emerging opportunities across the global ophthalmic medical device sector.

Market Overview

The global Ophthalmic Perfluoropropane Gas (C3F8) market is projected to grow from US$ 77.28 million in 2025 to US$ 111 million in 2032, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2026 to 2032.

In 2025, global production of Ophthalmic Perfluoropropane Gas (C3F8) reached approximately 160 k units, with an average global market price of approximately US$495 per unit.

Product Profile

• Description: Ophthalmic perfluoropropane gas (C3F8) is a colorless, odorless, non-toxic, and chemically stable inert gas that is insoluble in water.
• Classification: Class III medical device.
• Standard Specifications: Typically 15ml.
• Primary Function & Mechanism: Used as a filling gas material in vitreo-retinal detachment surgery. It functions by absorbing nitrogen and oxygen in the surrounding tissue and expanding, which creates a supporting effect on the retina to promote reduction and healing.
• Clinical Benefits: Plays a critical role in eye surgery by improving surgical cure rates, reducing surgical risks and complications, simplifying the surgical process, and reducing the workload of physicians.

Market Dynamics

Growth Drivers

• Clinical Demand: As an essential intraocular tamponade material in vitreoretinal surgery, market demand is directly linked to the global burden of ophthalmic diseases.
• Demographic & Health Trends: Global population aging, the rising prevalence of myopia, and the spread of chronic eye diseases (such as diabetic retinopathy) are collectively driving stable clinical demand for long-acting intraocular filling gases.
• Surgical Advancements: The widespread adoption of minimally invasive vitrectomy has increased the clinical usage frequency of this product.
• Standardization: The standardization of surgical techniques has promoted market penetration across medical institutions at various levels.

Market Entry Barriers & Challenges

• Technical Barriers: Production requires high technical proficiency with strict requirements for gas purity, impurity control, and sterile processing.
• Regulatory Oversight: Major global markets classify the product as a high-risk medical device, necessitating strict supervision.
• Registration & Verification: Long product registration cycles and high requirements for clinical verification constitute significant barriers to entry.
• Environmental & Supply Chain Constraints: The production of fluorine-containing gases is subject to global environmental protection policies. Raw material supply and capacity planning must comply with national greenhouse gas emission control requirements, posing challenges to supply chain stability and flexibility.

Report Scope & Methodology

Produced by LP Information, Inc. (LPI), the “Ophthalmic Perfluoropropane Gas (C3F8) Industry Forecast” provides a comprehensive analysis of the global landscape. The report reviews total world sales in 2025 and provides projected sales analysis for the period from 2026 through 2032.

The report covers:

• Market Analysis: Detailed analysis in US$ millions by region, market sector, and sub-sector.
• Competitive Landscape: Trends related to product segmentation, company formation, revenue, market share, latest developments, and M&A activity.
• Strategic Insights: Analysis of leading global companies regarding their C3F8 portfolios, capabilities, market entry strategies, market positions, and geographic footprints.
• Methodology: A transparent approach based on hundreds of bottom-up qualitative and quantitative market inputs to provide a nuanced view of the current state and future trajectory.

Market Segmentation

By Type

• Pure C3F8
• Gas Mixture

By Specification

• 30 ml/unit
• 40 ml/unit
• Others

By Application

• Retinal Detachment Repair
• Macular Hole Surgery
• Others

By End-user

• Hospital
• Ophthalmology Clinic

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key companies profiled are selected based on primary expert input and analysis of company coverage, product portfolios, and market penetration:

• Alcon
• Alchimia
• Scott Medical
• DORC (ZEISS)
• Pharmpur
• BVI Medical
• Fluoron GmbH
• Micromed
• Shanghai Jesvis Medical Technology

Key Questions Addressed

• What is the 10-year outlook for the global Ophthalmic Perfluoropropane Gas (C3F8) market?
• What factors are driving Ophthalmic Perfluoropropane Gas (C3F8) market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Ophthalmic Perfluoropropane Gas (C3F8) market opportunities vary by end market size?
• How does Ophthalmic Perfluoropropane Gas (C3F8) break out by Type and by End-user?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Ophthalmic Perfluoropropane Gas (C3F8) by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Ophthalmic Perfluoropropane Gas (C3F8) by Country/Region, 2021, 2025 & 2032

  • 2.2 Ophthalmic Perfluoropropane Gas (C3F8) Segment by Type

    • 2.2.1 Pure C3F8

    • 2.2.2 Gas Mixture

    • 2.2.3 Ophthalmic Perfluoropropane Gas (C3F8) Sales by Type

      • 2.2.3.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Sales Market Share by Type (2021-2026)
      • 2.2.3.2 Global Ophthalmic Perfluoropropane Gas (C3F8) Revenue and Market Share by Type (2021-2026)
      • 2.2.3.3 Global Ophthalmic Perfluoropropane Gas (C3F8) Sale Price by Type (2021-2026)

  • 2.3 Ophthalmic Perfluoropropane Gas (C3F8) Segment by Specification

    • 2.3.1 30 ml/unit

    • 2.3.2 40 ml/unit

    • 2.3.3 Others

    • 2.3.4 Ophthalmic Perfluoropropane Gas (C3F8) Sales by Specification

      • 2.3.4.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Sales Market Share by Specification (2021-2026)
      • 2.3.4.2 Global Ophthalmic Perfluoropropane Gas (C3F8) Revenue and Market Share by Specification (2021-2026)
      • 2.3.4.3 Global Ophthalmic Perfluoropropane Gas (C3F8) Sale Price by Specification (2021-2026)

  • 2.4 Ophthalmic Perfluoropropane Gas (C3F8) Segment by Application

    • 2.4.1 Retinal Detachment Repair

    • 2.4.2 Macular Hole Surgery

    • 2.4.3 Others

    • 2.4.4 Ophthalmic Perfluoropropane Gas (C3F8) Sales by Application

      • 2.4.4.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Sales Market Share by Application (2021-2026)
      • 2.4.4.2 Global Ophthalmic Perfluoropropane Gas (C3F8) Revenue and Market Share by Application (2021-2026)
      • 2.4.4.3 Global Ophthalmic Perfluoropropane Gas (C3F8) Sale Price by Application (2021-2026)

  • 2.5 Ophthalmic Perfluoropropane Gas (C3F8) Segment by End-user

    • 2.5.1 Hospital

    • 2.5.2 Ophthalmology Clinic

    • 2.5.3 Ophthalmic Perfluoropropane Gas (C3F8) Sales by End-user

      • 2.5.3.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Sale Market Share by End-user (2021-2026)
      • 2.5.3.2 Global Ophthalmic Perfluoropropane Gas (C3F8) Revenue and Market Share by End-user (2021-2026)
      • 2.5.3.3 Global Ophthalmic Perfluoropropane Gas (C3F8) Sale Price by End-user (2021-2026)

• 3 Global by Company

  • 3.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Breakdown Data by Company

    • 3.1.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Annual Sales by Company (2021-2026)

    • 3.1.2 Global Ophthalmic Perfluoropropane Gas (C3F8) Sales Market Share by Company (2021-2026)

  • 3.2 Global Ophthalmic Perfluoropropane Gas (C3F8) Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Revenue by Company (2021-2026)

    • 3.2.2 Global Ophthalmic Perfluoropropane Gas (C3F8) Revenue Market Share by Company (2021-2026)

  • 3.3 Global Ophthalmic Perfluoropropane Gas (C3F8) Sale Price by Company

  • 3.4 Key Manufacturers Ophthalmic Perfluoropropane Gas (C3F8) Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Ophthalmic Perfluoropropane Gas (C3F8) Product Location Distribution

    • 3.4.2 Players Ophthalmic Perfluoropropane Gas (C3F8) Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Ophthalmic Perfluoropropane Gas (C3F8) by Geographic Region

  • 4.1 World Historic Ophthalmic Perfluoropropane Gas (C3F8) Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Ophthalmic Perfluoropropane Gas (C3F8) Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Ophthalmic Perfluoropropane Gas (C3F8) Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Ophthalmic Perfluoropropane Gas (C3F8) Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Ophthalmic Perfluoropropane Gas (C3F8) Sales Growth

  • 4.4 APAC Ophthalmic Perfluoropropane Gas (C3F8) Sales Growth

  • 4.5 Europe Ophthalmic Perfluoropropane Gas (C3F8) Sales Growth

  • 4.6 Middle East & Africa Ophthalmic Perfluoropropane Gas (C3F8) Sales Growth

• 5 Americas

  • 5.1 Americas Ophthalmic Perfluoropropane Gas (C3F8) Sales by Country

    • 5.1.1 Americas Ophthalmic Perfluoropropane Gas (C3F8) Sales by Country (2021-2026)

    • 5.1.2 Americas Ophthalmic Perfluoropropane Gas (C3F8) Revenue by Country (2021-2026)

  • 5.2 Americas Ophthalmic Perfluoropropane Gas (C3F8) Sales by Type (2021-2026)

  • 5.3 Americas Ophthalmic Perfluoropropane Gas (C3F8) Sales by End-user (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Ophthalmic Perfluoropropane Gas (C3F8) Sales by Region

    • 6.1.1 APAC Ophthalmic Perfluoropropane Gas (C3F8) Sales by Region (2021-2026)

    • 6.1.2 APAC Ophthalmic Perfluoropropane Gas (C3F8) Revenue by Region (2021-2026)

  • 6.2 APAC Ophthalmic Perfluoropropane Gas (C3F8) Sales by Type (2021-2026)

  • 6.3 APAC Ophthalmic Perfluoropropane Gas (C3F8) Sales by End-user (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Ophthalmic Perfluoropropane Gas (C3F8) by Country

    • 7.1.1 Europe Ophthalmic Perfluoropropane Gas (C3F8) Sales by Country (2021-2026)

    • 7.1.2 Europe Ophthalmic Perfluoropropane Gas (C3F8) Revenue by Country (2021-2026)

  • 7.2 Europe Ophthalmic Perfluoropropane Gas (C3F8) Sales by Type (2021-2026)

  • 7.3 Europe Ophthalmic Perfluoropropane Gas (C3F8) Sales by End-user (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Ophthalmic Perfluoropropane Gas (C3F8) by Country

    • 8.1.1 Middle East & Africa Ophthalmic Perfluoropropane Gas (C3F8) Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Ophthalmic Perfluoropropane Gas (C3F8) Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Ophthalmic Perfluoropropane Gas (C3F8) Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Ophthalmic Perfluoropropane Gas (C3F8) Sales by End-user (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Ophthalmic Perfluoropropane Gas (C3F8)

  • 10.3 Manufacturing Process Analysis of Ophthalmic Perfluoropropane Gas (C3F8)

  • 10.4 Industry Chain Structure of Ophthalmic Perfluoropropane Gas (C3F8)

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Ophthalmic Perfluoropropane Gas (C3F8) Distributors

  • 11.3 Ophthalmic Perfluoropropane Gas (C3F8) Customer

• 12 World Forecast Review for Ophthalmic Perfluoropropane Gas (C3F8) by Geographic Region

  • 12.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Market Size Forecast by Region

    • 12.1.1 Global Ophthalmic Perfluoropropane Gas (C3F8) Forecast by Region (2027-2032)

    • 12.1.2 Global Ophthalmic Perfluoropropane Gas (C3F8) Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Ophthalmic Perfluoropropane Gas (C3F8) Forecast by Type (2027-2032)

  • 12.7 Global Ophthalmic Perfluoropropane Gas (C3F8) Forecast by End-user (2027-2032)

• 13 Key Players Analysis

  • 13.1 Alcon

    • 13.1.1 Alcon Company Information

    • 13.1.2 Alcon Ophthalmic Perfluoropropane Gas (C3F8) Product Portfolios and Specifications

    • 13.1.3 Alcon Ophthalmic Perfluoropropane Gas (C3F8) Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Alcon Main Business Overview

    • 13.1.5 Alcon Latest Developments

  • 13.2 Alchimia

    • 13.2.1 Alchimia Company Information

    • 13.2.2 Alchimia Ophthalmic Perfluoropropane Gas (C3F8) Product Portfolios and Specifications

    • 13.2.3 Alchimia Ophthalmic Perfluoropropane Gas (C3F8) Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Alchimia Main Business Overview

    • 13.2.5 Alchimia Latest Developments

  • 13.3 Scott Medical

    • 13.3.1 Scott Medical Company Information

    • 13.3.2 Scott Medical Ophthalmic Perfluoropropane Gas (C3F8) Product Portfolios and Specifications

    • 13.3.3 Scott Medical Ophthalmic Perfluoropropane Gas (C3F8) Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 Scott Medical Main Business Overview

    • 13.3.5 Scott Medical Latest Developments

  • 13.4 DORC (ZEISS)

    • 13.4.1 DORC (ZEISS) Company Information

    • 13.4.2 DORC (ZEISS) Ophthalmic Perfluoropropane Gas (C3F8) Product Portfolios and Specifications

    • 13.4.3 DORC (ZEISS) Ophthalmic Perfluoropropane Gas (C3F8) Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 DORC (ZEISS) Main Business Overview

    • 13.4.5 DORC (ZEISS) Latest Developments

  • 13.5 Pharmpur

    • 13.5.1 Pharmpur Company Information

    • 13.5.2 Pharmpur Ophthalmic Perfluoropropane Gas (C3F8) Product Portfolios and Specifications

    • 13.5.3 Pharmpur Ophthalmic Perfluoropropane Gas (C3F8) Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 Pharmpur Main Business Overview

    • 13.5.5 Pharmpur Latest Developments

  • 13.6 BVI Medical

    • 13.6.1 BVI Medical Company Information

    • 13.6.2 BVI Medical Ophthalmic Perfluoropropane Gas (C3F8) Product Portfolios and Specifications

    • 13.6.3 BVI Medical Ophthalmic Perfluoropropane Gas (C3F8) Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 BVI Medical Main Business Overview

    • 13.6.5 BVI Medical Latest Developments

  • 13.7 Fluoron GmbH

    • 13.7.1 Fluoron GmbH Company Information

    • 13.7.2 Fluoron GmbH Ophthalmic Perfluoropropane Gas (C3F8) Product Portfolios and Specifications

    • 13.7.3 Fluoron GmbH Ophthalmic Perfluoropropane Gas (C3F8) Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 Fluoron GmbH Main Business Overview

    • 13.7.5 Fluoron GmbH Latest Developments

  • 13.8 Micromed

    • 13.8.1 Micromed Company Information

    • 13.8.2 Micromed Ophthalmic Perfluoropropane Gas (C3F8) Product Portfolios and Specifications

    • 13.8.3 Micromed Ophthalmic Perfluoropropane Gas (C3F8) Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 Micromed Main Business Overview

    • 13.8.5 Micromed Latest Developments

  • 13.9 Shanghai Jesvis Medical Technology

    • 13.9.1 Shanghai Jesvis Medical Technology Company Information

    • 13.9.2 Shanghai Jesvis Medical Technology Ophthalmic Perfluoropropane Gas (C3F8) Product Portfolios and Specifications

    • 13.9.3 Shanghai Jesvis Medical Technology Ophthalmic Perfluoropropane Gas (C3F8) Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.9.4 Shanghai Jesvis Medical Technology Main Business Overview

    • 13.9.5 Shanghai Jesvis Medical Technology Latest Developments

• 14 Research Findings and Conclusion